Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial

Peer Review reports

Original Submission
23 Mar 2022	Submitted	Original manuscript
16 Jun 2022	Reviewed	Reviewer Report - Kirsty Loudon
18 Sep 2022	Reviewed	Reviewer Report - Lucio Jesus García-Fraile García Fraile
18 Oct 2022	Author responded	Author comments - Shaukat Ali
Resubmission - Version 2
18 Oct 2022	Submitted	Manuscript version 2
Publishing
21 Oct 2022	Editorially accepted
8 Nov 2022	Article published	10.1186/s13063-022-06860-2

Back to article page